Sift Biosciences: Valuation, Funding & Investors
Sift Biosciences is developing a peptide-based immunotherapy platform designed to harness pre-existing immune memory. The company aims to activate memory T cells to generate more consistent immune engagement, with applications across oncology and autoimmune diseases and an initial focus on immunologically cold solid tumors such as microsatellite-stable colorectal and ovarian cancers.
Leadership & Board
- Current Number of Employees
- 10
- Current LinkedIn Followers
- 1,312
Latest Estimated Valuation
- Total Amount Raised
- $4M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $4M
- Latest Funding Round
- Pre-Seed
Employee Trend
Sift Biosciences had 10 employees as of November 16, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
Sift Biosciences had 1,312 followers as of November 16, 2026. The number of followers increased by 11 (0.85%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Feb 18, 2026 | Pre-Seed | $3.70M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Eisai Innovation | Pre-Seed |
| Freeflow Ventures | Pre-Seed |
| LifeSpan Vision Ventures | Pre-Seed |
| SBI US Gateway Fund | Pre-Seed |
| Valuence Ventures | Pre-Seed |
Similar Companies
A snapshot of private companies similar to Sift Biosciences, helping you discover and navigate related company profiles.
Related News and Analysis







